Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04908995 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

A Phase 1 study of Healthy Adults, sponsored by EicOsis Human Health.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT04908995 is a Phase 1 study of Healthy Adults that has completed, run by EicOsis Human Health. The registered enrollment target is 18 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04908995, a Phase 1 study of Healthy Adults, has completed, sponsored by EicOsis Human Health.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.

Conditions Studied

Interventions

  • DRUG EC5026 oral tablet
  • OTHER Placebo oral tablet

Study Locations (1)

Texas

  • PPD Phase I Clinic - Austin

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2021-04-30
Est. Completion 2021-11-24
Phase Phase 1

Sponsor

EicOsis Human Health

5 total trials

What the Registry Record Tells You About NCT04908995

The ClinicalTrials.gov registry entry for NCT04908995 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (79% lower). The listed sponsor is EicOsis Human Health, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which EC5026 oral tablet is the first listed.

NCT04908995 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04908995 about?

NCT04908995 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects". The purpose of the study is to provide safety, tolerability, pharmacokinetics and food effects data of a single 8 mg oral dose of EC5026 in healthy subjects.

What is the current status of trial NCT04908995?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-04-30. Estimated completion is 2021-11-24.

What conditions does trial NCT04908995 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT04908995?

The interventions under investigation include: EC5026 oral tablet (DRUG), Placebo oral tablet (OTHER).

Who is sponsoring clinical trial NCT04908995?

This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04908995 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.